ArticleFrontiers in oncology2026
Preoperative HAIC enlarges future liver remnant in initial unresectable HCC patients with Vp3 tumor thrombus.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Conversion strategy is the optimal treatment for patients with unresectable hepatocellular carcinoma (uHCC). However, a severe lack of future liver remnant (FLR) may result in early withdrawal. In this small sample retrospective study, we investigated FLR changes after conversion therapies. Notably, patients with ipsilateral Vp3 portal vein tumor thrombus (PVTT) showed a significant FLR increase after treatment and provided an advantage for carrying out radical surgery. Methods: 53 uHCC patients with Vp0 to Vp3 tumor thrombus were enrolled and divided into two groups (Vp0-2 and Vp3) based on the initial PVTT status. All patients received anti-PD-L1 and anti-VEGF therapy combined with hepatic arterial infusion chemotherapy (HAIC) every three weeks. The FLR was measured at baseline and after 3-4 cycles. The odds ratio (OR) between Vp3 and FLR changes was calculated. Results: Among the 53 patients, 28 achieved complete response (CR) or partial response (PR) after conversion treatment. FLR did not change in Vp0-2 group, regardless of the response. While a significant FLR increase was observed in Vp3 group, especially in patients with CR and PR. 10 cases of successfully converted Vp3 patients showed an average FLR enlargement of 18.5%. Conclusion: According to our study, Vp3 patients demonstrated greater FLR enlargement after conversion therapy combined with HAIC, probably due to the thrombus' restriction on blood flow to the tumor side liver. This observation may help to increase both the surgeons' and the uHCC patients' confidence in continuing treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.